PL
CLYM

Parkwood LLC’s Climb Bio CLYM Stock Holding History

Parkwood LLC’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-67,202
Closed -$203K – 177
2022
Q2 		$203K Buy
67,202
+26,069
+63% +$123K 0.04% 131
2022
Q1 		$345K Buy
41,133
+10,524
+34% +$98.2K 0.06% 111
2021
Q4 		$320K Buy
+30,609
New +$456K 0.05% 106

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parkwood LLC's CLYM Position: Q3 2022 in Review

Parkwood LLC sold out of Climb Bio (CLYM) in Q3 2022, closing a stake of 67,202 shares — an estimated $203K sold.

Parkwood LLC first reported a position in CLYM in Q4 2021 and held it in 3 quarters. The position peaked at $345K in Q1 2022. 22 funds tracked by Wall St. Rank hold CLYM as of Q3 2022.

  • Parkwood LLC reported no remaining Climb Bio position as of Q3 2022 after selling out during the quarter.
  • Parkwood LLC sold 67,202 Climb Bio shares in Q3 2022, an estimated $203K.
  • Parkwood LLC first reported a position in Climb Bio in Q4 2021 and held it in 3 quarters.
  • Parkwood LLC's Climb Bio position peaked at $345K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Climb Bio as of Q3 2022.

Based on Parkwood LLC's 13F filing for Q3 2022, filed 14 Nov 2022.